In vitro activity of the new quinolone WCK 771 against staphylococci

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3338-3342

  Jacobs, Michael R ^a,d   Bajaksouzian, Saralee ^a   Windau, Anne ^a   Appelbaum, Peter C ^b   Patel, Mahesh V ^c   Gupte, Shrikant V ^c   Bhagwat, Sachin S ^c   De Souza, Noel J ^c   Khorakiwala, Habil F ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c Wockhardt Research Centre   (India)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 771;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; EFFUSION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PUMP; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; KINETICS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUINOLONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 4344630939     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3338-3342.2004     Document Type: Article

References (28)

1. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
2. Calderon-Jaimes, E., L. E. Espinosa de los Monteros, and R. Avila-Beltran. 2002. Epidemiology of drug resistance: the case of Staphylococcus aureus and coagulase-negative staphylococci infections. Salud Publica Mex. 44:108-812.
3. Centers for Disease Control and Prevention. 2002. Public health dispatch: vancomycin resistant Staphylococcus aureus - Pennsylvania, 2002. Morb. Mortal. Wkly. Rep. 51:902.
4. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
5. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Canto, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
6. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
7. Drlica, K. 2001. A strategy for fighting antibiotic resistance. ASM News 67:27-33.
8. Drlica, K., and M. Malik. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3:249-282.
9. Fluit, A. C., M. E. Jones, F. J. Schmitz, J. Acar, R. Gupta, and J. Verhoef. 2000. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin. Infect. Dis. 30:454-460.
10. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. C. Tenover. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439.
11. Gould, I. M., K. Milne, and C. Jason. 1990. Concentration-dependent bacterial killing, adaptive resistance and post-antibiotic effect of ciprofloxacin alone and in combination with gentamicin. Drugs Exp. Clin. Res. 16:621-628.
12. Herington, J. A., J. A. Fedirici, and J. M. Remy. 2000. Factors affecting the in vitro activity of moxifloxacin, p. 73-79. In D. Adam and R. Finch (ed.), Moxifloxacin in practice. Maxim Medical, Oxford, United Kingdom.
13. Hooper, D. C. 2002. Fluoroquinolone resistance among gram-positive cocci. Lancet Infect. Dis, 2:530-538.
14. Jones, M. E., M. R. Visser, M. Klootwijk, P. Heisig, J. Verhoef, and F. J. Schmitz. 1999. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 43:421-423.
15. Kimata, H. 1999. Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur. J. Pediatr. 158:949.
16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Nishijima, S., I. Kurokawa, and H. Nakaya. 2002. Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J. Infect. Chemother. 8:187-189.
18. Nishijima, S., and M. Nakagawa. 1997. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients. J. Int. Med. Res. 25:210-213.
19. Nishijima, S., M. Nakagawa, N. Tsuboi, H. Akamatsu, T. Horio, M. Fujita, and S. Kawabata. 1996. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. J. Int. Med. Res. 24:12-16.
20. Nishijima, S., S. Namura, H. Akamatsu, S. Kawai, Y. Asada, S. Kawabata, and M. Fujita. 1995. In vitro activity of nadifloxacin against both methicillin- susceptible and -resistant clinical isolates of Staphylococcus aureus from patients with skin infections. Drugs 49(Suppl. 2):230-232.
21. Oizumi, N., S. Kawabata, M. Hirao, K. Watanabe, S. Okuno, T. Fujiwara, and M. Kikuchi. 2001. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J. Infect. Chemother. 7:191-194.
22. Pankuch, G, A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
23. Pong, A., K. S. Thomson, E. S. Moland, S. A. Chartrand, and C. C. Sanders. 1999. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemother. 44:621-627.
24. 6-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 21:27-34.
25. Schmitz, F. J., A. C. Fluit, M. Luckefahr, B. Engler, B. Hofmann, J. Verhoef, H. P. Heinz, U. Hadding, and M. E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
26. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
27. Takei, M., H. Fukuda, R. Kishii, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
28. Thomson, C. J. 1999. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob. Chemother. 43(Suppl. A):31-40.